ASX Release **31 October 2024**

Quarterly Activities Report: Continued execution of clinical trial strategy considerably derisks lead program

- **Maiden dosing of TRP-8803 (IV-infused psilocin) administered in global first, marking commencement of Phase 1b healthy human volunteer study**
- **Completion of Phase 1b TRP-8803 trial with all participants administered IV-infusion for up to 150 minutes and safely discharged – Pending results will define and optimise dosing rate for future clinical studies**
- **Phase 2a study utilising TRP-8802 (oral psilocybin) completed with University of Michigan into the treatment of fibromyalgia – five patients dosed with clinically significant results generated**
- **All patients dosed with TRP-8802 during UOM study reported an improvement in Fibromyalgia pain severity, sleep, pain interference and at least 3 other end points measured one month after dosing**
- **Patients in UOM study also recorded clinically meaningful improvements in quality-of-life measures including sleep, physical activity and participation in social activities**
- **Phase 2a trial utilising TRP-8802 commenced with Massachusetts General Hospital for the treatment of Irritable Bowel Syndrome – marking the first time MGH has administered psilocybin in a clinical study**
- **MGH is founding member of the Mass General Brigham health system and Harvard's oldest hospital**
- **Key appointments to Scientific Advisory Board included distinguished psychiatry professor, Professor David Castle and highly regarded professor, Professor Phillipa Hay**
- **Post quarter end, the Company secured firm commitments to raise $6m at $0.02 per new share with an attaching option for every two new shares subscribed for via a strategic placement**
- **Placement is strongly supported by a range of new and existing stakeholders including cornerstone investors, the high conviction Merchant Biotech Fund and Dr Daniel Tillett**
- **Initiative also supported by existing major shareholders Dr Bill Garner, Mr Herwig Janssen and Mr Ludwig Criel – Commitments from CEO Mr Jason Carroll and Director, Mr Chris Ntoumenopoulos also received**
- **Upon completion of placement, Dr Daniel Tillett will be appointed a Non-Executive Director while Mr Clarke Barlow will step down as a Director of the Company**
- **New funding highlights considerable momentum TYP has built for future clinical trials utilising TRP-8803 into specific indications**

Melbourne, Australia – Tryptamine Therapeutics Limited ('**Tryp**' or the '**Company**') (**ASX: TYP**), a clinical-stage biotechnology company, is pleased to provide the following update on activities undertaken during the three-month period ended 31 September 2024 (the 'quarter').

During the quarter, Tryp continued to execute on its stated clinical trial strategy, which has laid a strong foundation for future trials utilising the Company's innovative TRP-8803 (IV-infused psilocin solution). TYP also made a number

of appointments to its Scientific Advisory Board and key management team. Subsequent to the end of the period, the Company considerably strengthened its balance sheet, securing firm commitments from a range of new and existing investors to raise $6m. This provides exceptional financial flexibility to advance TYP's clinical trial pipeline.

Operational overview:

Maiden dosing of TRP-8803 (IV-infused psilocin) completed in global first:

During the quarter, the company advised it had safely and successfully completed first dosing using TRP-8803 in a participant in Adelaide, South Australia. This marked the start of Tryp's planned Phase 1b (healthy human volunteer study), which aims to aims to refine and optimise dosing and infusion rates of TRP-8803 to achieve precise blood levels of psilocin with an acceptable pharmacokinetics profile in up to 12 participants and to determine its safety prior to additional clinical studies which will be focused on particular need states.

The participant was administered with TRP-8803, the Company's innovative IV-infused psilocin solution, for approximately 140 minutes and progressed through the treatment safely. The participant was discharged after dosing follow-up was completed.

TRP-8803, Tryp's lead program alleviates a number of significant shortcomings of oral psilocybin therapy. Potential advantages of the IV-infused psilocin solution include a significant reduction in the time to onset of the psychedelic state, more precise control of the depth and duration of the psychedelic experience and a reduction in the overall duration of the intervention to a commercially feasible timeframe.

Completion of Phase 1b study utilising TRP-8803:

Shortly after the completion of first dosing, the Company advised it had completed its maiden Phase 1b study. As part of the initiative, TRP-8803 was successfully administered for a period of up to 150 minutes to a total of 11 participants, each of whom were safely discharged following treatment and dosing follow-up.

Safety Review Council review of all data is now underway, which will determine if results meet the proposed safety criteria of the trial. The Company will provide further updates on results as they materialise. Positive results will provide a strong foundation for future trials using TRP-8803, which will be focused on specific clinical indications including Binge Eating Disorder and Fibromyalgia.

Completion of Phase 2a study for the treatment of fibromyalgia with the University of Michigan (UOM):

Tryp's trial in collaboration with top-ranked, US public university UOM commenced in January 2024 with the aim of evaluating TRP-8802 (oral psilocybin) in conjunction with psychotherapy to treat patients with fibromyalgia, a condition associated with widespread pain and tenderness.

Five participants were dosed with TRP-8802 during the trial and administered psychotherapy to explore TRP-8802's utility in patients with fibromyalgia. Researchers from the University of Michigan presented study results at the International Association of Pain Conference in the Netherlands on 9 August 2024. This provided the Company with exceptional exposure to industry experts, as well as potential collaborators and partners.

Positive Phase 2a fibromyalgia results deliver pain reduction in 100% of patients:

Results from the Phase 2a delivered exceptional results, including a 100% of patients experience a reduction in fibromyalgia pain, sleep disturbance and pain interreference. Other conclusions drawn in the study included that psilocybin assisted therapy was safe and well tolerated in participants, and that these results further strengthen TYP's intellectual property position.

The results also serve to validate Tryp's clinical trial approach targeting nociplastic pain with an initial focus on fibromyalgia and will inform an additional clinical study utilising TRP-8803 (IV-infused psilocin), which is expected to commence H1 2025. Results from the trial are set out in the following charts:



Figure one: Individual patient (001-005) and pooled results highlighting improvements in fibromyalgia domains as presented by UOM on 9 August 2024 (adapted)



Figure two: Indicates secondary outcome. Chronic Pain Acceptance Questionnaire (CPAQ). Pain severity as change in aggregate pain score from the seven dates prior to the intervention to the end of the intervention. Sleep disturbance, pain interference, physical function, anxiety, depression, fatigue, participation in social activities, and cognitive abilities are all reported as T-scores, per PROMIS scoring. Negative change scores indicate improvement for pain severity, pain interference, sleep disturbance, fibromyalgia score, anxiety, depression, and fatigue. Positive change scores indicate improvement for CPAQ, physical function. Participation in social activities, and cognitive abilities.

TYP continues to work alongside UOM to further define the results, which will be used to inform future clinical studies utilising TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, and safety, along with

enhancing both the patient and therapist experience.

First patient dosed at Massachusetts General Hospital for Tryp's Phase 2a study for the treatment of Irritable Bowel Syndrome (IBS):

The Company completed first patient dosing in its Phase 2a clinical trial investigating the treatment of IBS has dosed at Massachusetts General Hospital ('MGH' or 'Mass General'). Importantly, this marks the first time that MGH has administered psilocybin in a clinical setting.

The trial will evaluate TRP-8802 (oral psilocybin) in conjunction with psychotherapy in patients with IBS, a common disorder which affects an individual's stomach and intestines. The primary efficacy endpoint is reduction in chronic abdominal pain and visceral tenderness. The open label exploratory trial will seek to dose up to ten participants that suffer from IBS with TRP-8802 administered in conjunction with psychotherapy to explore the effectiveness of the combination in treating IBS patients. Additional participants will be dosed over the coming months, with results anticipated in Q1 2025.

MGH is a significant clinical trial partner. It is home to the largest hospital-based research enterprise in the US, with an annual budget of US$1.2Bn in 2021. The Mass General Research Institute comprises more than 9,500 researchers working across over 30 institutes, centres and departments. Mass General has been a leader in bridging innovative science with highly advanced clinical care for more than 200 years.

Per the Company's stated strategy, results will be used to inform additional clinical studies into IBS utilising TRP-8803 (IV-infused psilocin), which has a number of potential advantages over oral dosing. The Company remains confident that this initiative and future work may provide a benefit to IBS sufferers in exploring the root cause of the condition, as well as treating its debilitating symptoms.

Key appointments to strengthen Scientific Advisory Board (SAB):

The company significantly strengthened its SAB during the period following the appointment of distinguished psychiatry professor, Professor David Castle and highly regarded professor, Professor Phillipa Hay. Both have agreed to undertake their roles on the SAB for a three-year period.

Professor Castle is a leading psychiatric scholar who was recently appointed by the Tasmanian Government as Professor of Psychiatry at the University of Tasmania's Centre for Mental Health Service Innovation, which was launched in partnership with the Tasmanian Department of Health.

Professor Hay is a highly regarded professor and Chair of Mental Health at Western Sydney University. Specifically, Professor Hay is an academic psychiatrist who is recognised internationally for her research and expertise in improving health outcomes associated with eating disorders and obesity. She has published over 500 Web of Science core collection scientific papers and regularly presents her work nationally and internationally. Her work has been influential in providing evidence-based research to inform clinical practice and establish national and international guidelines for the treatment of eating disorders.

The Company looks forward to leveraging their respective expertise across its clinical trial pipeline and through grant funding opportunities.

Financial overview:

$6m million secured in new funding to fast track clinical trial opportunities:

Subsequent to the end of the period, the Company advised it has received firm commitments from new and existing professional, sophisticated and institutional investors to raise $6m through the issue of 300m new fully paid ordinary shares (Shares) at an issue price of $0.02 per share (Placement).

The Placement was cornerstoned by the Merchant Biotech Fund ('MBF') and distinguished biotech investor Dr Daniel Tillett. It was also being supported by existing major shareholders, Dr Bill Garner, Mr Herwig Janssen and Mr Ludwig Criel, as well as CEO Mr Jason Carroll and Company Director Mr Chris Ntoumenopoulos (subject to shareholder approval).

The MBF is a high conviction fund, focused on emerging opportunities in the biotechnology sector. The fund is underpinned by considerable internal expertise and investment knowledge and has provided strong returns since inception.

Funds from the Placement will be used to accelerate the Company's development of TRP-8803 (IV-infused psilocin), including additional, larger clinical trials utilising TRP-8803 in specific indications. This is anticipated to provide pivotal clinical data, prior to the commencement of product registration in the Australian market.

Full details of the offer can be found in the company's ASX announcement dated 30 October 2024.

Commentary on cash flow:

Tryp ended the quarter with cash of $2.8 million ($5.3 million at 30 June 2024), with net operating cash outflows for the period of $2.3 million ($2.3 million net operating cash outflows in the prior quarter). Cash outflow for the period predominately related to TRP-8803 clinical trial costs and significant one-off costs relating to the acquisition and re-listing transaction, including legal and professional fees and insurance related costs. This has been buoyed following the Company's recently completed Placement to raise $6 million (refer ASX announcement: 30 October 2024).

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates gross salaries, superannuation and fees and benefits to executive and non-executive directors.

Use of funds:

In accordance with ASX Listing Rule 4.7C2, the Company provides the following (unaudited) update on its use of funds against amounts set out in the Prospects:

Indicative use of funds	Estimated total per prospectus	Actual cash outflows (1 May – 30 Sep 24)
R&D – Project Management & Analysis	$2,485,000	$723,345
Completion of Phase 2a Fibromyalgia trial at University of Michigan	$150,000	$40,756
Completion of Phase 2a Irritable Bowel Syndrome trial at Mass General Hospital (Harvard)	$200,000	-

Completion of TRP-8803 dosing study in Australia including initial GMP manufacturing	$1,050,000	$1,633,597
	$241,000	$202,621
Completion of Phase 2 trial in Binge Eating Disorder using TRP 8803	$540,000	-
Completion of Phase 2 trial in Chronic Pain Fibromyalgia using TRP 8803	$375,000	-
Technical staff	$700,000	-
Lead Manager/ Corporate Advisor fees	$462,000	$280,050
Transaction and IPO costs	$532,000	$566,342
Working Capital for Corporate Uses	$3,870,485	$1,934,686
Total funds	**$10,605,485**	**$5,381,397**

Corporate:

Appointment of Chief Financial Officer (CFO):

Mr Hamish George was appointed CFO, effective 1 September 2024, replacing Mr Jim O'Neill. Mr George is a Director at Bio101 Financial Advisory ('Bio101'), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Board and management team look forward to leveraging Mr George's expertise in the biotechnology and healthcare sector as the Company advances its extensive clinical trial pathway.

TYP would also like to extend its gratitude to Mr Jim O'Neill for his service and wish him well for future endeavours.

Board transition:

Subsequent to the end of the period and following the announcement of the Company's strategic Placement, Dr Daniel Tillett has agreed to be appointed as a Non-Executive Director of the Company. Dr Tillett is the founder and CEO of Nucleics, an Australian biotechnology company focused on the development of software tools that improve DNA sequencing and genomics. He was also previously Chief Scientific Officer and Executive Director of Race Oncology Limited (ASX: RAC) between September 2019 and March 2023, before undertaking the Chief Executive Officer role at the Company, prior to transitioning to his current role as CEO/Managing Director during CY2024.

Dr Tillett holds a PhD in Biochemistry and Molecular Biology from UNSW and brings nearly 30 years' experience in the biotechnology sector to TYP. Dr Tillett will assist the ongoing development of the Company's clinical trial strategy and commercialisation opportunities.

Following Dr Tillett's appointment, Non-Executive Director Mr Clarke Barlow has decided to step down from the Board of Directors following the AGM. The Company thanks him for service and wish him both well for future

endeavours.

During the period, Chief Business Officer and Executive Director Mr Peter Molloy transitioned to a Non-Executive Director. The transition results in cost savings for the Company and a streamlined executive management team, aligned with Tryp's ongoing focus on Australian operations.

Management commentary:

Chief Executive Officer, Mr. Jason Carroll said: *"Tryp's operational progress in the recent quarter has been firmly focused on delivering milestones to form a strong foundation for future trials utilising TRP-8803. The completion of our phase 1b study in Adelaide showed that the solution can be deployed into healthy volunteers, all of which were safely discharged after treatment. Further to this, the Company delivered very promising results in a separate trial highlighting that oral psilocybin can be used to treat symptoms associated with fibromyalgia. The results for this trial were clinically meaningful and provide the Company with added confidence in its planned clinical development pathway. We look forward to continuing work with Massachusetts General Hospital to replicate these results in pursuit of improved health outcomes for IBS.*

"Post quarter end, the Company secured firm commitments from a range of sophisticated and institutional investors to raise $6m in new funding. This highlights considerable validation of the Company's strategy and work to date. It will also provide exceptional financial flexibility as Tryp seeks to advance larger clinical trials using TRP-8803 in specific indications."

"We are now laser focused on aggressively advancing the clinical pipeline for TRP-8803. A number of potential trials into specific indications are actively being assessed, all of which are very large market opportunities. We look forward to providing further updates to shareholders as they materialise."

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

TRYPTAMINE THERAPEUTICS LIMITED

ACN	**Quarter ended ("current quarter")**
163 765 991	30 September 2024

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(986)	(986)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	(42)	(42)
	(d) leased assets	-	-
	(e) staff costs	(407)	(407)
	(f) administration and corporate costs	(1,041)	(1,041)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	1
1.5	Interest and other costs of finance paid	(2)	(2)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	165	165
1.9	**Net cash from / (used in) operating activities**	**(2,312)**	**(2,312)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(3)	(3)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(3)**	**(3)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(227)	(227)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	-	-
	Other (bank guarantee and security deposit)	-	-
3.10	**Net cash from / (used in) financing activities**	**(227)**	**(227)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	5,328	5,328
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,312)	(2,312)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3)	(3)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(227)	(227)
4.5	Effect of movement in exchange rates on cash held	(18)	(18)
4.6	**Cash and cash equivalents at end of period**	**2,768**	**2,768**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	2,768	5,328
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**2,768**	**5,328**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	260
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

The payments to directors or their associates in 6.1 include gross salaries, superannuation and fees and benefits to executive and non-executive directors.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)		
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(2,312)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	2,768
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	2,768
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	**1.2**

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Future net operating cash outflows is expected to differ to current net operating cash outflows due to an expected reduction in corporate and administration cost. In the current period, corporate and administration costs contained one-off costs relating to the acquisition and re-listing transaction.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: As announced on 30 October 2024, the Company has received firm commitments to raise $6M via a strategic placement. In addition, the Company is anticipating to receive an R&D rebate for eligible FY2024 expenses.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes, the Company is sufficiently funded to continue its operations and meet its business objectives. The Company will continue to maintain eligibility for nondilutive funding through the R&D Tax Incentive scheme, as well as continue to evaluate its capital requirements and options.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2024

Authorised by: Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.